BD

bioSeedin attended 2023 BIO international convention for international licensing and partnership

Retrieved on: 
Wednesday, June 21, 2023
Database, BIO, DSM-IV codes, Partnership, Respiratory disease, Cardiovascular disease, Research, Risk, GCT, BD, Video game, Pharmaceutical industry

BOSTON, June 19, 2023 /PRNewswire/ -- bioSeedin, a global transaction and consultation platform, attended as an exhibitor at the world's largest biotech trade event BIO international convention, held in Boston from June 5th to June 8th, 2023.

Key Points: 
  • BOSTON, June 19, 2023 /PRNewswire/ -- bioSeedin, a global transaction and consultation platform, attended as an exhibitor at the world's largest biotech trade event BIO international convention, held in Boston from June 5th to June 8th, 2023.
  • Pharmaceutical companies from the United States, Europe, Japan, Korea, Australia, and other countries held in-depth conversations about bioSeedin's highlighted asset projects and partnership modes.
  • As a rising service provider in this field, bioSeedin has developed a multi-dimensional business model to cater to the diverse needs of its clients.
  • The weekly webinar of bioSeedin gathers 50,000+ global audiences with 200-600 attendees each time, while the two annual meetings attract thousands of attendees for Company Roadshow and One-on-One Partnering.

STERIS Expands Healthcare Products Offering with Acquisition of Surgical Instrumentation Assets from Becton, Dickinson and Company for $540 million

Retrieved on: 
Tuesday, June 20, 2023
LLP, STE, Health care, Tax, Instrument, Sterilization, Acquisition, Lazard, Transaction, Steris, BD (company), Hand, BDX, NYSE, BD, Security (finance)

STERIS anticipates that the acquisition will qualify for a tax benefit related to tax deductible goodwill, with a present value of approximately $60 million.

Key Points: 
  • STERIS anticipates that the acquisition will qualify for a tax benefit related to tax deductible goodwill, with a present value of approximately $60 million.
  • The acquisition includes V. MuellerTM, Snowden-PencerTM and GenesisTM branded products, which are well-known providers of surgical instruments and sterilization containers to Healthcare Customers.
  • “We welcome these teams to STERIS and look forward to working together to enhance our value to our Customers.”
    Under the terms of the agreement, STERIS will purchase surgical instrumentation, laparoscopic instrumentation and sterilization containers assets from BD at closing.
  • Lazard is serving as financial advisor to STERIS and Thompson Hine LLP is serving as legal counsel for this Transaction.

Molecular Templates Announces Debt Payoff and Restructuring

Retrieved on: 
Saturday, June 17, 2023
Workforce, Therapy, Cancer, Sale, Climate Change and Emissions Management Amendment Act, BMS, BD, Pharmaceutical industry, Stifel

AUSTIN, Texas, June 16, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, announced today that it has entered into a restructuring agreement (“Amending Agreement”) with K2 HealthVentures (“K2HV”) to satisfy and discharge MTEM’s outstanding secured debt obligations and terminate all other obligations under the existing debt financing facility between Molecular Templates and K2HV.

Key Points: 
  • AUSTIN, Texas, June 16, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, announced today that it has entered into a restructuring agreement (“Amending Agreement”) with K2 HealthVentures (“K2HV”) to satisfy and discharge MTEM’s outstanding secured debt obligations and terminate all other obligations under the existing debt financing facility between Molecular Templates and K2HV.
  • Molecular Templates also announced a restructuring plan that includes reducing its current workforce as it continues to explore strategic alternatives.
  • In connection with the evaluation of strategic alternatives and in order to extend its resources to better position the organization, Molecular Templates today implemented a restructuring plan that includes reducing its current workforce by approximately 44%.
  • Molecular Templates intends to continue to support its collaboration with BMS and its clinical studies.

Global Clinical Laboratory Tests Market Report 2023: Sector is Expected to Reach $213.04 Billion by 2030 at a CAGR of 9.4% - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 15, 2023
Pharmaceutical, Science, Health, Research, Therapy, Prevalence, Diabetes, Kidney, CVD, Death, Tuberculosis, Laboratory, Disease, Growth, Mortality, Ageing, WHO, Microbiology, BD, Pharmaceutical industry

The growth of the clinical laboratory tests market is attributable to the rising prevalence of target diseases.

Key Points: 
  • The growth of the clinical laboratory tests market is attributable to the rising prevalence of target diseases.
  • The global geriatric population is increasing and is considered as being the greatest risk factor for the development of conditions, such as cardiovascular diseases and kidney dysfunction.
  • Thus, the growing geriatric population is expected to be a high-impact rendering driver for this market over the forecast period.
  • In addition, increasing adoption of laboratory automation systems is expected to boost the market over the forecast period.

Computer Vision Market to Hit $58.29 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Thursday, June 15, 2023
Component, Contact tracing, Communication, University, Vaccination, Onderlinge van 1719 u.a., Smartphone, Facial recognition, Deep learning, Health status of Asian Americans, Convolutional neural network, COVID-19, Lens, Power plant engineering, Automotive industry, Research, SAN, USD, Government, Movement, CNN, Computer, Automation, Application, Investment, Patient, Patient safety, AI2, Champaign–Urbana metropolitan area, Algorithm, Artificial intelligence, Growth, City, AI, Omron, Allen Institute, BD, Revenue, Software, Retail, Shipbuilding, Video game, Medical device, Speciality chemicals, ALHOSN University, Health care

SAN FRANCISCO, June 15, 2023 /PRNewswire/ -- The global computer vision market size is expected to reach USD 58.29 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, June 15, 2023 /PRNewswire/ -- The global computer vision market size is expected to reach USD 58.29 billion by 2030, according to a new report by Grand View Research, Inc.
  • The expanding number of adoptions of computer vision globally is projected to support market expansion.
  • Read full market research report, " Computer Vision Market Size, Share & Trends Analysis Report By Component, By Product Type, By Application, By Vertical (Automotive, Healthcare, Retail), By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • A boom in the manufacturing sector is anticipated to enhance the market demand for machine vision in the Asia Pacific region.

Computer Vision Market to Hit $58.29 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Thursday, June 15, 2023
Component, Contact tracing, Communication, University, Vaccination, Onderlinge van 1719 u.a., Smartphone, Facial recognition, Deep learning, Health status of Asian Americans, Convolutional neural network, COVID-19, Lens, Power plant engineering, Automotive industry, Research, SAN, USD, Government, Movement, CNN, Computer, Automation, Application, Investment, Patient, Patient safety, AI2, Champaign–Urbana metropolitan area, Algorithm, Artificial intelligence, Growth, City, AI, Omron, Allen Institute, BD, Revenue, Software, Retail, Shipbuilding, Video game, Medical device, Speciality chemicals, ALHOSN University, Health care

SAN FRANCISCO, June 15, 2023 /PRNewswire/ -- The global computer vision market size is expected to reach USD 58.29 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, June 15, 2023 /PRNewswire/ -- The global computer vision market size is expected to reach USD 58.29 billion by 2030, according to a new report by Grand View Research, Inc.
  • The expanding number of adoptions of computer vision globally is projected to support market expansion.
  • Read full market research report, " Computer Vision Market Size, Share & Trends Analysis Report By Component, By Product Type, By Application, By Vertical (Automotive, Healthcare, Retail), By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • A boom in the manufacturing sector is anticipated to enhance the market demand for machine vision in the Asia Pacific region.

BD Launches New Robotic System to Automate Clinical Flow Cytometry

Retrieved on: 
Monday, June 12, 2023
Cancer, Automation, Becton, Dickinson and Company headquarters, BD, Flow cytometry, IVD, Diagnosis, Becton, Robotics, BDX, NYSE, Medical device, Computer data storage

FRANKLIN LAKES, N.J., June 12, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the worldwide commercial launch of a new automated instrument that prepares samples for clinical diagnostics using flow cytometry, enabling a complete "walkaway" workflow solution designed to improve standardization and reproducibility in cellular diagnostics.

Key Points: 
  • The BD FACSDuet™ Premium Sample Preparation System leverages liquid-handling robotics to automate the entire sample preparation process, for both in vitro diagnostics (IVD) and user-defined tests, including cocktailing, washing and centrifuging – and then automatically transfers samples to the physically integrated BD FACSLyric™ Clinical Flow Cytometry System, without human interaction.
  • By being integrated with the flow cytometer, the BD FACSDuet™ Premium System enables a "walkaway" workflow solution that requires fewer manual steps, fewer resources and less user hands-on time than previous solutions.
  • Flow cytometry is an essential tool for clinical diagnostics, commonly utilized in the diagnosis and management of diseases like cancer.
  • The BD FACSDuet™ Premium System is now available to order through local sales representatives.

Delve Expands Services with Digital Innovation and Design Firm Acquisition

Retrieved on: 
Friday, June 2, 2023
App Store (iOS/iPadOS), Acquisition, BD, Retail

MADISON, Wis., June 2, 2023 /PRNewswire/ -- Delve continues to grow into the world's leading innovation consultancy with its acquisition of altr , a digital innovation and design company.

Key Points: 
  • MADISON, Wis., June 2, 2023 /PRNewswire/ -- Delve continues to grow into the world's leading innovation consultancy with its acquisition of altr , a digital innovation and design company.
  • The acquisition strengthens Delve's ability to deliver products, services, and experiences to clients that seamlessly combine physical and digital features.
  • "The future is about delivering a unified product experience – digital, physical, and service," said Delve President Andrew Weiman.
  • "Our clients will now be able to achieve that future with a single innovation partner, Delve."

EQS-News: Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease

Retrieved on: 
Friday, June 2, 2023
BIO, Therapy, IgG4-related ophthalmic disease, Senior, CMC, Geographic atrophy, ATMP, AAV, CDMO, Eye, Patient, BD, Vaccine, Pharmaceutical industry

Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel gene therapy for the treatment of geographic atrophy.

Key Points: 
  • Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel gene therapy for the treatment of geographic atrophy.
  • Dr. Katie Binley, Chief Scientific Officer of Ikarovec, said: “We are delighted to collaborate with Rentschler Biopharma on our lead program.
  • Dr. Christian Schetter, Chief Scientific Officer of Rentschler Biopharma, added: “With Rentschler Biopharma’s ATMP offering, we aim to address an important gap in specific support for innovative, early-stage cell and gene therapy programs.
  • Ikarovec and its novel candidate are a perfect fit for our services.

Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease

Retrieved on: 
Thursday, June 1, 2023
BIO, Therapy, IgG4-related ophthalmic disease, Senior, CMC, Geographic atrophy, ATMP, AAV, CDMO, Eye, Patient, NORWICH, BD, Vaccine, Pharmaceutical industry

Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel gene therapy for the treatment of geographic atrophy.

Key Points: 
  • Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel gene therapy for the treatment of geographic atrophy.
  • Dr. Katie Binley, Chief Scientific Officer of Ikarovec, said: “We are delighted to collaborate with Rentschler Biopharma on our lead program.
  • Dr. Christian Schetter, Chief Scientific Officer of Rentschler Biopharma, added: “With Rentschler Biopharma’s ATMP offering, we aim to address an important gap in specific support for innovative, early-stage cell and gene therapy programs.
  • Ikarovec and its novel candidate are a perfect fit for our services.